FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220848708> ?p ?o ?g. }

• W4220848708 abstract "We determined first- and second-line regimens, including hematopoietic stem cell transplantations, in all diffuse large B cell lymphoma (DLBCL) patients aged ≥20 yr (n = 1,888), registered at the Belgian Cancer Registry (2013-2015). Treatments were inferred from reimbursed drugs, and procedures registered in national health insurance databases. This real-world population-based study allows to assess patients usually excluded from clinical trials such as those with comorbidities, other malignancies (12%), and advanced age (28% are ≥80 yr old). Our data show that the majority of older patients are still started on first-line regimens with curative intent and a substantial proportion of them benefit from this approach. First-line treatments included full R-CHOP (44%), incomplete (R-)CHOP (18%), other anthracycline (14%), non-anthracycline (9%), only radiotherapy (3%), and no chemo-/radiotherapy (13%), with significant variation between age groups. The 5-year overall survival (OS) of all patients was 56% with a clear influence of age (78% [20-59 yr] versus 16% [≥85 yr]) and of the type of first-line treatments: full R-CHOP (72%), other anthracycline (58%), incomplete (R-)CHOP (47%), non-anthracycline (30%), only radiotherapy (30%), and no chemo-/radiotherapy (9%). Second-line therapy, presumed for refractory (7%) or relapsed disease (9%), was initiated in 252 patients (16%) and was predominantly (71%) platinum-based. The 5-year OS after second-line treatment without autologous stem cell transplantation (ASCT) was generally poor (11% in ≥70 yr versus 17% in <70 yr). An ASCT was performed in 5% of treated patients (n = 82). The 5-year OS after first- or second-line ASCT was similar (69% versus 66%). After adjustment, multivariable OS analyses indicated a significant hazard ratio (HR) for, among others, age (HR 1.81 to 5.95 for increasing age), performance status (PS) (HR 4.56 for PS >1 within 3 months from incidence), subsequent malignancies (HR 2.50), prior malignancies (HR 1.34), respiratory and diabetic comorbidity (HR 1.41 and 1.24), gender (HR 1.25 for males), and first-line treatment with full R-CHOP (HR 0.41) or other anthracycline-containing regimens (HR 0.72). Despite inherent limitations, patterns of care in DLBCL could be determined using an innovative approach based on Belgian health insurance data." @default.
• W4220848708 created "2022-04-03" @default.
• W4220848708 creator A5025968794 @default.
• W4220848708 creator A5052758475 @default.
• W4220848708 creator A5054416214 @default.
• W4220848708 creator A5057954503 @default.
• W4220848708 creator A5064080897 @default.
• W4220848708 creator A5068846608 @default.
• W4220848708 creator A5069014502 @default.
• W4220848708 date "2022-02-28" @default.
• W4220848708 modified "2023-10-16" @default.
• W4220848708 title "Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study" @default.
• W4220848708 cites W1895923234 @default.
• W4220848708 cites W1967008538 @default.
• W4220848708 cites W1972771318 @default.
• W4220848708 cites W2018071905 @default.
• W4220848708 cites W2123439935 @default.
• W4220848708 cites W2126779872 @default.
• W4220848708 cites W2129337227 @default.
• W4220848708 cites W2131424155 @default.
• W4220848708 cites W2133159533 @default.
• W4220848708 cites W2135471715 @default.
• W4220848708 cites W2136060045 @default.
• W4220848708 cites W2147246240 @default.
• W4220848708 cites W2150587745 @default.
• W4220848708 cites W2152655727 @default.
• W4220848708 cites W2159862107 @default.
• W4220848708 cites W2167556523 @default.
• W4220848708 cites W2310716991 @default.
• W4220848708 cites W2523392153 @default.
• W4220848708 cites W2551074936 @default.
• W4220848708 cites W2559431510 @default.
• W4220848708 cites W2577385476 @default.
• W4220848708 cites W2598700764 @default.
• W4220848708 cites W2620269048 @default.
• W4220848708 cites W2744261860 @default.
• W4220848708 cites W2767945001 @default.
• W4220848708 cites W2782542634 @default.
• W4220848708 cites W2797584152 @default.
• W4220848708 cites W2801763724 @default.
• W4220848708 cites W2809084663 @default.
• W4220848708 cites W2890722938 @default.
• W4220848708 cites W2895341926 @default.
• W4220848708 cites W2898597172 @default.
• W4220848708 cites W2911578541 @default.
• W4220848708 cites W2915065822 @default.
• W4220848708 cites W2919538398 @default.
• W4220848708 cites W2948321946 @default.
• W4220848708 cites W2951658597 @default.
• W4220848708 cites W2965210018 @default.
• W4220848708 cites W2972587086 @default.
• W4220848708 cites W2981315734 @default.
• W4220848708 cites W2995669627 @default.
• W4220848708 cites W3016044607 @default.
• W4220848708 cites W3034704434 @default.
• W4220848708 cites W3091903979 @default.
• W4220848708 cites W3103124792 @default.
• W4220848708 cites W3103667486 @default.
• W4220848708 cites W3120997411 @default.
• W4220848708 cites W3131555873 @default.
• W4220848708 cites W3135547922 @default.
• W4220848708 cites W3144369660 @default.
• W4220848708 cites W3172657081 @default.
• W4220848708 cites W3176654461 @default.
• W4220848708 cites W3189823837 @default.
• W4220848708 cites W3200337778 @default.
• W4220848708 cites W3202324966 @default.
• W4220848708 cites W4205736005 @default.
• W4220848708 doi "https://doi.org/10.3389/fonc.2022.824704" @default.
• W4220848708 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35299736" @default.
• W4220848708 hasPublicationYear "2022" @default.
• W4220848708 type Work @default.
• W4220848708 citedByCount "3" @default.
• W4220848708 countsByYear W42208487082023 @default.
• W4220848708 crossrefType "journal-article" @default.
• W4220848708 hasAuthorship W4220848708A5025968794 @default.
• W4220848708 hasAuthorship W4220848708A5052758475 @default.
• W4220848708 hasAuthorship W4220848708A5054416214 @default.
• W4220848708 hasAuthorship W4220848708A5057954503 @default.
• W4220848708 hasAuthorship W4220848708A5064080897 @default.
• W4220848708 hasAuthorship W4220848708A5068846608 @default.
• W4220848708 hasAuthorship W4220848708A5069014502 @default.
• W4220848708 hasBestOaLocation W42208487081 @default.
• W4220848708 hasConcept C121608353 @default.
• W4220848708 hasConcept C126322002 @default.
• W4220848708 hasConcept C141071460 @default.
• W4220848708 hasConcept C143998085 @default.
• W4220848708 hasConcept C2776802502 @default.
• W4220848708 hasConcept C2778559949 @default.
• W4220848708 hasConcept C2779338263 @default.
• W4220848708 hasConcept C2779725641 @default.
• W4220848708 hasConcept C2908647359 @default.
• W4220848708 hasConcept C509974204 @default.
• W4220848708 hasConcept C530470458 @default.
• W4220848708 hasConcept C71924100 @default.
• W4220848708 hasConcept C99454951 @default.
• W4220848708 hasConceptScore W4220848708C121608353 @default.
• W4220848708 hasConceptScore W4220848708C126322002 @default.
• W4220848708 hasConceptScore W4220848708C141071460 @default.
• W4220848708 hasConceptScore W4220848708C143998085 @default.

• next